Here, we will describe effector and exhausted CD8+ T cell differentiation in the tumor microenvironment, explore transcription factors and genomic alterations reinvigorating such differentiation, and examine therapies which target these epigenetic pathways as a means to enhance the efficacy of ICB therapy. The gene discussed is CD8A; the disease is neoplasm.